Actuate Therapeutics (ACTU) News Today $7.22 +0.31 (+4.49%) Closing price 04/3/2025 03:59 PM EasternExtended Trading$8.05 +0.83 (+11.50%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Actuate Therapeutics files to sell 3.9M shares of common stock for holdersMarch 29, 2025 | markets.businessinsider.comActuate Therapeutics: Looking To Make An Impact In Pancreatic CancerMarch 26, 2025 | seekingalpha.comWhat is HC Wainwright's Forecast for ACTU Q1 Earnings?Actuate Therapeutics (NASDAQ:ACTU - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Actuate Therapeutics in a report issued on Monday, March 17th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of ($0.26) forMarch 20, 2025 | marketbeat.comActuate Therapeutics (NASDAQ:ACTU) Now Covered by HC WainwrightHC Wainwright began coverage on shares of Actuate Therapeutics in a research report on Monday. They issued a "buy" rating and a $20.00 price objective on the stock.March 18, 2025 | marketbeat.comHC Wainwright & Co. Initiates Coverage of Actuate Therapeutics (ACTU) with Buy RecommendationMarch 18, 2025 | msn.comActuate Therapeutics initiated with a Buy at H.C. WainwrightMarch 17, 2025 | markets.businessinsider.comActuate Therapeutics: Promising Phase 2 Results and Market Potential for Elraglusib in Metastatic Pancreatic CancerMarch 17, 2025 | tipranks.comActuate Therapeutics (NASDAQ:ACTU) Shares Up 4.5% - Here's What HappenedActuate Therapeutics (NASDAQ:ACTU) Trading 4.5% Higher - Time to Buy?March 2, 2025 | marketbeat.comCandel Therapeutics stock drops despite OS improvement in PDAC trialFebruary 27, 2025 | msn.comActuate Therapeutics completes enrollment in Phase 2 trial of elraglusibFebruary 25, 2025 | msn.comIs Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans?February 12, 2025 | finance.yahoo.comActuate Therapeutics sets annual meeting for May 22February 8, 2025 | msn.comActuate Therapeutics to Participate in Upcoming Investor Conferences in FebruaryFebruary 6, 2025 | globenewswire.comActuate Therapeutics' (NASDAQ:ACTU) Lock-Up Period Set To Expire on February 10thActuate Therapeutics' (NASDAQ:ACTU - Get Free Report) lock-up period will expire on Monday, February 10th. Actuate Therapeutics had issued 2,800,000 shares in its initial public offering on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.February 3, 2025 | marketbeat.comActuate Therapeutics (NASDAQ:ACTU) Stock Price Down 5.4% - What's Next?Actuate Therapeutics (NASDAQ:ACTU) Stock Price Down 5.4% - Should You Sell?January 30, 2025 | marketbeat.comEMA gives OMPD to Actuate’s pancreatic cancer therapyJanuary 8, 2025 | msn.comActuate Therapeutics announces EMA granted OMPD to elraglusibJanuary 8, 2025 | markets.businessinsider.comActuate Therapeutics (NASDAQ:ACTU) Shares Down 2.1% - Time to Sell?Actuate Therapeutics (NASDAQ:ACTU) Stock Price Down 2.1% - Should You Sell?January 8, 2025 | marketbeat.comActuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic CancerJanuary 7, 2025 | markets.businessinsider.comActuate Therapeutics announces interim Phase 2 data of elraglusibDecember 18, 2024 | markets.businessinsider.comActuate Therapeutics Shares Rise 12% on Positive Phase 2 Trial to Treat Metastatic Pancreatic Ductal CancerDecember 17, 2024 | marketwatch.comActuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic CancerDecember 17, 2024 | globenewswire.comActuate Therapeutics announces new data from Phase 2 trial of elraglusibDecember 17, 2024 | tipranks.comActuate Therapeutics (NASDAQ:ACTU) Trading 0.8% Higher - Here's What HappenedActuate Therapeutics (NASDAQ:ACTU) Stock Price Up 0.8% - What's Next?December 17, 2024 | marketbeat.comActuate Therapeutics (NASDAQ:ACTU) Stock Quotes, Forecast and News SummaryDecember 13, 2024 | benzinga.comActuate Therapeutics to be Added to Russell 2000® IndexNovember 26, 2024 | finance.yahoo.comActuate Therapeutics added to Russell 2000 IndexNovember 26, 2024 | tipranks.comActuate Therapeutics to join Russell 2000 indexNovember 26, 2024 | seekingalpha.comActuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing SarcomaNovember 12, 2024 | finance.yahoo.comActuate Therapeutics: FDA Grants Pediatric-Disease Status to Ewing Sarcoma TreatmentNovember 12, 2024 | marketwatch.comActuate Therapeutics (NASDAQ:ACTU) Trading Down 2.8% - Should You Sell?Actuate Therapeutics (NASDAQ:ACTU) Shares Down 2.8% - Here's What HappenedOctober 31, 2024 | marketbeat.comActuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug DevelopmentOctober 29, 2024 | globenewswire.comActuate Therapeutics Inc ACTUOctober 9, 2024 | morningstar.comActuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β InhibitorSeptember 23, 2024 | finance.yahoo.comActuate Therapeutics' (NASDAQ:ACTU) Quiet Period Set To Expire on September 23rdActuate Therapeutics' (NASDAQ:ACTU - Get Free Report) quiet period will expire on Monday, September 23rd. Actuate Therapeutics had issued 2,800,000 shares in its IPO on August 13th. The total size of the offering was $22,400,000 based on an initial share price of $8.00. During the company's quiet period, insiders and any underwriters involved in the IPO are prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.September 16, 2024 | marketbeat.comActuate Therapeutics: Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue SarcomasSeptember 11, 2024 | finanznachrichten.deActuate Gets FDA Orphan Designation for Elraglusib in Soft Tissue SarcomasSeptember 11, 2024 | marketwatch.comActuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing SarcomaSeptember 9, 2024 | globenewswire.comActuate to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | globenewswire.comActuate therapeutics insider sells $150,000 worth of sharesAugust 18, 2024 | investing.comActuate Therapeutics Inc (ACTU)August 17, 2024 | investing.comActuate Therapeutics (NASDAQ:ACTU) Insider Todd S. Thomson Sells 18,750 SharesAugust 17, 2024 | insidertrades.comBuy Rating Affirmed for Brainstorm Cell Therapeutics Amid Strategic Advances and Robust FinancialsAugust 16, 2024 | markets.businessinsider.comActuate Therapeutics, Inc. Common stock (ACTU)August 15, 2024 | ca.finance.yahoo.comActuate Therapeutics (NASDAQ:ACTU) Major Shareholder Leslie W. Kreis Sells 24,999 SharesAugust 15, 2024 | insidertrades.comActuate Therapeutics Announces Closing of Initial Public OfferingAugust 14, 2024 | globenewswire.comActuate Therapeutics Announces Pricing of Initial Public OfferingAugust 12, 2024 | globenewswire.com Remove Ads Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address ACTU Media Mentions By Week ACTU Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACTU News Sentiment▼0.300.61▲Average Medical News Sentiment ACTU News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACTU Articles This Week▼11▲ACTU Articles Average Week Remove Ads Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies OPT News Today URGN News Today SAGE News Today ARVN News Today MAZE News Today PRTC News Today TYRA News Today SION News Today AKBA News Today RLAY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACTU) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
